Safety concerns with
erythropoietin analogues and intravenous (IV)
iron for treatment of
anemia in CKD necessitate development of safer
therapies.
Roxadustat (FG-4592) is an orally bioavailable
hypoxia-inducible factor (HIF)
prolyl hydroxylase inhibitor that promotes coordinated erythropoiesis through HIF-mediated transcription. We performed an open-label, randomized
hemoglobin (Hb) correction study in anemic (Hb≤10.0 g/dl) patients incident to
hemodialysis (HD) or
peritoneal dialysis (PD). Sixty patients received no
iron, oral
iron, or IV
iron while treated with
roxadustat for 12 weeks. Mean±SD baseline Hb was 8.3±1.0 g/dl in enrolled patients.
Roxadustat at titrated doses increased mean Hb by ≥2.0 g/dl within 7 weeks regardless of baseline
iron repletion status,
C-reactive protein level,
iron regimen, or dialysis modality. Mean±SEM maximal change in Hb from baseline (ΔHb(max)), the primary endpoint, was 3.1±0.2 g/dl over 12 weeks in efficacy-evaluable patients (n=55). In groups receiving oral or IV
iron, ΔHb(max) was similar and larger than in the no-
iron group. Hb response (increase in Hb of ≥1.0 g/dl from baseline) was achieved in 96% of efficacy-evaluable patients. Mean serum
hepcidin decreased significantly 4 weeks into study: by 80% in HD patients receiving no
iron (n=22), 52% in HD and PD patients receiving oral
iron (n=21), and 41% in HD patients receiving IV
iron (n=9). In summary,
roxadustat was well tolerated and corrected
anemia in incident HD and PD patients, regardless of baseline
iron repletion status or
C-reactive protein level and with oral or IV
iron supplementation; it also reduced serum
hepcidin levels.